Perfil
Frank Baas was the founder of Regenesance BV, which was founded in 2009, where he held the title of Chief Scientific Officer from 2009 to 2016.
He was a Professor at the University of Amsterdam and a Member at Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh from 1989 to 1996.
Dr. Baas earned a doctorate degree from the University of Amsterdam in 1982 and another doctorate degree from the same university in 1986.
Antiguos cargos conocidos de Frank Baas.
| Empresas | Cargo | Fin |
|---|---|---|
Regenesance BV
 Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | Fundador | 01/07/2016 |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | 01/01/1996 |
| University of Amsterdam | Corporate Officer/Principal | - |
Formación de Frank Baas.
| University of Amsterdam | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Regenesance BV
Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | Retail Trade |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Miscellaneous |
- Bolsa de valores
- Insiders
- Frank Baas
